Us 23-Valent Pneumococcal Polysaccharide Vaccine Market Size By Applications, By Type, By End-User, By Deployment & By Technology 2032
23-Valent Pneumococcal Polysaccharide Vaccine Market was valued at USD 0.94 Billion in 2022 and is projected to reach USD 1.27 Billion by 2030, growing at a CAGR of 4.1% from 2024 to 2030.
The U.S. 23-valent pneumococcal polysaccharide vaccine (PPSV23) market is experiencing significant growth, driven by increasing awareness and recent advancements in vaccine development. This vaccine, designed to protect against 23 strains of Streptococcus pneumoniae, plays a crucial role in preventing severe infections such as pneumonia, meningitis, and bloodstream infections, particularly among adults over 50 and individuals with weakened immune systems.
In October 2024, the Centers for Disease Control and Prevention (CDC) expanded its vaccination recommendations to include adults aged 50-64, a demographic previously not covered. This policy shift aims to reduce the incidence of pneumococcal diseases in this age group, thereby broadening the vaccine's market reach.
Market dynamics have been further influenced by emerging biotech companies challenging established pharmaceutical giants. Notably, Vaxcyte, a biotech startup, has developed VAX-31, an experimental vaccine targeting 31 strains of pneumococcal bacteria. In early-stage trials, VAX-31 elicited immune responses comparable to or exceeding those of Pfizer's Prevnar 20 across all tested strains. At higher doses, VAX-31 outperformed Prevnar 20 in 18 of the 20 strains tested. These promising results have positioned Vaxcyte as a formidable competitor in the pneumococcal vaccine market, potentially reshaping the landscape dominated by Pfizer and Merck.
Financial projections reflect this competitive shift. The global 23-valent pneumococcal polysaccharide vaccine market was valued at approximately $1.17 billion in 2022 and is projected to reach $2.26 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.8%. This growth is attributed to increased vaccination rates, expanded age indications, and the introduction of innovative vaccines like VAX-31.
From a personal perspective, witnessing the rapid evolution of the pneumococcal vaccine market is both fascinating and encouraging. The entry of innovative biotech firms introduces healthy competition, leading to more effective vaccines and improved public health outcomes. As someone who has closely followed vaccine developments, the advancements in this field underscore the importance of continued investment in research and development to combat infectious diseases effectively.
In summary, the U.S. 23-valent pneumococcal polysaccharide vaccine market is undergoing transformative changes. Expanded CDC recommendations and the emergence of new market players like Vaxcyte are key drivers of this growth. These developments not only enhance vaccine accessibility but also promise to improve health outcomes for a broader segment of the population.
Get an In-Depth Research Analysis of the Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size And Forecast [2025-2032]
MSD
Sanofipasteur
CDIBP
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global 23-Valent Pneumococcal Polysaccharide Vaccine Market
Pediatric Population
Adult Population
Elderly Population (65+ years)
Hospitals
Pharmacies
Clinics
Public Health Centers
Preventive Vaccination
Diagnostic Use
Therapeutic Use
Routine Immunization
Catch-Up Immunization
Travel Vaccination
Healthcare Providers
Government Health Programs
Private Clinics
Research Institutions
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ 23-Valent Pneumococcal Polysaccharide Vaccine Market Research Analysis
1. Introduction of the Global 23-Valent Pneumococcal Polysaccharide Vaccine Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, By Type
6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, By Application
7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/